

C-section causes a disruption in the gut microbiota of infants.

The first 1000 days of life represent a unique window of opportunity to shape immune health. A balanced gut microbiota is key for the development of a healthy immune system¹.


Caesarean section (C-section) is one of the most significant causes of disrupted microbiota development in infants due to reduced mother-infant transmission of beneficial bacteria².

39% OF ALL
BABIES BORN IN
AUSTRALIA ARE
BORN BY
C-SECTION³.

How does mode of delivery affect microbiota colonisation in an infant's gut?

Mode of delivery is a major factor that influences initial gut microbiota colonisation4:

- Vaginally delivered infants are exposed to maternal vaginal and faecal microbes which then colonise in the gut⁴;
- Babies delivered by C-section are more likely to be colonised by maternal skin and environmental microbes⁴;
- This gut dysbiosis in C-section can persist for as long as seven years and is associated with higher risk of certain diseases⁵.



For infants with risk factors for gut dysbiosis, it is important to provide nutrition that can restore the gut microbiota and therefore prevent health-related consequences. Dietary intervention shows that positive modulation of the gut microbiome is possible¹⁴.



Gut dysbiosis in C-section-born infants can be corrected in days.

Breast milk is the gold standard in infant nutrition¹⁵. When exclusive breastfeeding is not possible, it is essential that infant formula works towards mimicking human milk as closely as possible.

The prebiotic mixture scGOS/IcFOS (9:1) added to our infant formulas is supported by a strong body of evidence with more than 40 clinical studies¹⁶. This prebiotic is often paired with the probiotic *Bifidobacterium breve*, one of the most predominant bifidobacterial species in human milk^{17,18} and in the gut of healthy breastfed infants^{19,20}.

Chua et al. showed in a randomised, double-blind controlled trial that this specific synbiotic mixture compensated the delayed colonisation of *Bifidobacterium* in infants born by C-section within days¹⁴. This specific mixture resulted in significantly higher levels of *Bifidobacteria*, resembling levels found in vaginally-born infants.



Figure 1. *Bifidobacteria* levels in C-section-born infants randomised to receive synbiotic (n=52) or control formula (n=50) from day 3/5 to week 4, versus vaginally-born reference. Adapted from Chua et al 2017 ¹⁴.



Aptamil Gold+ contains a unique prebiotic and probiotic blend which is proven to bring the gut microbiota of C-section born infants who consume formula closer to vaginally born infants within days[†].

†Based on total scGOS/IcFOS (9:1) and *Bifidobacterium breve* M-16V received by formula-fed infants as per Aptamil Gold+ Stage 1 feeding guides. Data on file.

For any support, contact our Careline team



Our qualified team of registered dietitians, nutritionists and a midwife are here to help. We have in-depth knowledge and expertise in the clinical and practical use of all our Nutricia products.

Call us on 1800 438 500 (Australia) or email: nutriciacareline@danone.com.au



REFERENCES

- 1. Wopereis H, et al. Pediatr Allergy Immunol. 2014;25:428-38.
- 2. Bogaert D, et al. Cell Host Microbe. 2023;31(3):447-60.
- 3. Australian Institute of Health and Welfare. National Core Maternity Indicators, Caesarean section. [Internet] Canberra (AU): AIHW.[updated 2024 Oct 15; cited 2025 Jan 14] Available from:

www. aihw. gov. au/reports/mothers-babies/national-core-maternity-indicators/contents/labour-and-birth-indicators/caesarean-section

- 4. Milani C, et al. Microbiol Mol Biol Rev. 2017;81(4):e00036-17.
- 5. Carpay NC, et al. PLoS One. 2022;17(11):e0277405.
- 6. Reyman M, et al. Commun Biol. 2021;4(1):1233.
- 7. Miller JE, et al. PLoS Medicine. 2020;17:e1003429.
- 8. Sevelsted A, et al. Pediatrics. 2015;135:e92-8.

- 9. Stokholm J, et al. Sci Trans Med. 2020;12:eaax9929.
- 10. Deoni SC, et al. AJNR Am J Neuroradiol. 2019;40:169-77.
- 11. Huang K, et al. Brain Res Bull. 2019;144:108-21.
- 12. Zhou Y, et al. Int J Environ Res Public Health. 2020;17(6):2003.
- 13. Chojnacki MR, et al. Early Hum Dev. 2019;129:52-9.
- 14. Chua MC, et al. J Paediatr Gastroenterol Nutr. 2017;65(1):102-6.
- 15. Wells JM, et al. Annu Rev Nutr. 2022;42:165-200.
- 16. Salminen S, et al. Nutrients. 2020;12(7):1952.
- 17. Martin R, et al. Appl Environ Microbiol. 2009;75(4):965-9.
- 18. Soto A, et al. J Pediatr Gastroenterol Nutr. 2014;59(1):78-88.
- 19. Matsuki T, et al. Appli Environ Microbiol. 1999;65(10):4506-12.
- 20. Mikami K, Kimura M, Takahashi H. Pharmaceuticals. 2012;5(6):629-42.

